Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy

Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy

Abstract Background Immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized cancer therapy. However, therapeutic targeting of inhibitory T cell receptors such as PD-1 not only initiates a broad immune response against tumors, but also causes severe adverse effects. An ideal future s...

Full description

Bibliographic Details
Main Authors: Simon Heumos, Sandra Dehn, Konstantin Bräutigam, Marius C. Codrea, Christian M. Schürch, Ulrich M. Lauer, Sven Nahnsen, Michael Schindler
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Cancer Cell International
Subjects:
Immunotherapy
cancer
Multiomics
Theranostics
Flow cytometry
FACS
Online Access:https://doi.org/10.1186/s12935-022-02710-y

Internet

https://doi.org/10.1186/s12935-022-02710-y

Similar Items